2-(6-Benzylamino-8-chloro-9-isopropyl-9H-purin-2-ylamino)-butan-1-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-(6-Benzylamino-8-chloro-9-isopropyl-9H-purin-2-ylamino)-butan-1-ol
• 英文别名: 2-[[6-(benzylamino)-8-chloro-9-propan-2-ylpurin-2-yl]amino]butan-1-ol
• 化学式: C₁₉H₂₅ClN₆O
• 分子量: 388.9
• InChiKey: HQIODPHSOSOALL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  87.9
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-[[9-(1-甲基乙基)-6-[(苯基甲基)氨基]-9H-嘌呤-2-基]氨基]-1-丁醇 在 N-氯代丁二酰亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以61%的产率得到2-(6-Benzylamino-8-chloro-9-isopropyl-9H-purin-2-ylamino)-butan-1-ol
  参考文献：
  名称：

  2,6,8,9-Tetrasubstituted Purines as New CDK1 Inhibitors

  摘要：

  Purine inhibitors of cyclin-dependent kinases attract attention as potential anticancer drugs because their first representative roscovitine recently entered clinical trials. Although well described in terms of structure-activity relationships, we still present here a novel modification of the purine scaffold influencing their inhibitory properties. The introduced C-8 substituents, however, lowered the CDK inhibitory activity of roscovitine, whereas the antiproliferative potential of several derivatives remained high. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00632-2

文献信息

• Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
  申请人：USTAV EXPERIMENTALNI BOTANIKY AV CR

  公开号：US20030191086A1

  公开（公告）日：2003-10-09

  Various substituted nitrogen heterocyclic derivatives and their pharmaceutically acceptable salt derivatives are provided for use as medicaments, and particularly, as antimitotic, anti-viral, anti-cancer, anti-degenerative, immunosuppressive, and anti-microbial drugs or, vaccines. These heterocyclic derivatives can be used as an active agent in a pharmaceutical, as well as a diagnostic utility. To this end, several families of heterocyclic derivatives are provided including pyrrolopyrimidines, pyrazolopyrimidines, purines, and imidazopyridines. In particular, certain tri-substituted and tetra-substituted purines and pyrazolopyrimidines and their deaza analogues are provided for inhibiting cyclin-dependent kinase (“cdk”) proteins, viruses, and immunostimulation.

  提供了各种取代的氮杂环衍生物及其药学上可接受的盐衍生物，用作药物，特别是作为抗有丝分裂、抗病毒、抗癌、抗变性、免疫抑制和抗微生物药物或疫苗。这些杂环衍生物可以用作药物的活性成分，也可以用作诊断工具。为此，提供了几个杂环衍生物家族，包括吡咯吡咯嘧啶、吡唑嘧啶、嘌呤和咪唑吡啶。特别地，提供了某些三取代和四取代的嘌呤和吡唑嘧啶及其去氮类似物，用于抑制细胞周期依赖性激酶（“cdk”）蛋白、病毒和免疫刺激。
• SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF
  申请人：Ustav Experimentalni Botaniky Akademie ved Ceské Republiky

  公开号：EP1147108B1

  公开（公告）日：2003-08-13
• US6552192B1
  申请人：——

  公开号：US6552192B1

  公开（公告）日：2003-04-22
• 2,6,8,9-Tetrasubstituted Purines as New CDK1 Inhibitors
  作者：Jiřı́ Moravec、Vladimı́r Kryštof、Jan Hanuš、Libor Havlı́ček、Daniela Moravcová、Květoslava Fuksová、Marek Kuzma、René Lenobel、Michal Otyepka、Miroslav Strnad

  DOI：10.1016/s0960-894x(03)00632-2

  日期：2003.9

  Purine inhibitors of cyclin-dependent kinases attract attention as potential anticancer drugs because their first representative roscovitine recently entered clinical trials. Although well described in terms of structure-activity relationships, we still present here a novel modification of the purine scaffold influencing their inhibitory properties. The introduced C-8 substituents, however, lowered the CDK inhibitory activity of roscovitine, whereas the antiproliferative potential of several derivatives remained high. (C) 2003 Elsevier Ltd. All rights reserved.